Evidence map›Paper›PMID 39733933›Full record

ArticleThe Journal of investigative dermatology2025

Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.

Camilla Strother, Nicole Bouffard, Olha Smolynets, Nancy R Graham, Evan A Elko, Beulah Sabundayo, Anna P Durbin, Stephen S Whitehead, Douglas J Taatjes, Beth D Kirkpatrick and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Camilla StrotherDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Nicole BouffardDepartment of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Microscopy Imaging Center, Center for Biomedical Shared Resources, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Olha SmolynetsDepartment of Medicine-Infectious Diseases, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Infectious Diseases, Jefferson Health, Abington, Pennsylvania, USA.
Nancy R GrahamDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Evan A ElkoDepartment of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Beulah SabundayoCenter for Immunization Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Anna P DurbinCenter for Immunization Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Stephen S WhiteheadLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Douglas J TaatjesDepartment of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Microscopy Imaging Center, Center for Biomedical Shared Resources, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Beth D KirkpatrickDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Department of Medicine-Infectious Diseases, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Laura GreeneDepartment of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Kristen K PierceDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Department of Medicine-Infectious Diseases, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
Sean A DiehlDepartment of Microbiology and Molecular Genetics, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA; Vaccine Testing Center, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA. Electronic address: sean.diehl@med.uvm.edu.

Funding

UVM Center for Biomedical Shared Resources (CBSR)C06OD030087 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TAATJES, DOUGLAS J. · 2020 to 2020
$5.5M
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineU01AI141997 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Sean A. Diehl, Anna Palmer Durbin · 2019 to 2026
$5.1M
NIAID NIH HHS HHSN272200900010CNIAID NIH HHS U01 AI141997NIH HHS C06 OD030087
6 · The paper itself

Abstract

Vaccination with the tetravalent live-attenuated dengue virus (DENV) vaccines TV003 and TV005 causes a mild, relatively localized erythematous maculopapular skin rash in most dengue-naïve vaccinees. Human challenge model DENV strains, DENV2Δ30 and DENV3Δ30, trigger a confluent skin rash over most of the body in most unvaccinated participants. To determine the etiology of these rashes, we performed in situ hybridization for DENV genome and assessed cellular infiltration by H&E staining in skin biopsies from humans infected with live-attenuated dengue vaccine DENV2Δ30 or DENV3Δ30 challenge strains. Sixty-three biopsies from 40 participants were included in the study, of which 43 biopsies from 32 patients contained intact RNA. Of these, 1 sample taken from a nonerythematous site from a DENV2Δ30-infected participant experiencing a rash was positive for DENV2 genome. Incidence and severity of lymphocytic infiltration were highest in rash biopsy samples than in those from noninvolved areas in participants experiencing a rash or from those taken from participants not experiencing a rash. These results indicate that the rash associated with infection with live-attenuated dengue vaccines or challenge strains is predominantly lymphocyte-driven perivascular dermal inflammation without local concomitant active viral replication.

Indexed as

DengueDengue VaccinesDengue VirusExanthemaGenome, ViralAdolescentAdultBiopsyFemaleHumansInflammationMaleMiddle AgedSkinVaccines, AttenuatedYoung AdultDengue VaccinesVaccines, AttenuatedChallenge virusDengue tetravalent attenuated vaccineimmunogenicityNeutralizing antibodiesViremia

Identifiers

PMID39733933
PMCPMC12202709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.